

July 12, 2021

GENOMICS

CLL FISH In-House Testing

Date effective: July 12, 2021

Background Information:

CLL FISH performed at the Shared Health Genomics laboratory was performed using the OGT Cytocell© CLL FISH probe sets. Quality and reliability of signal strength from these probes was found to be less consistent over time. This decrease in quality was observed within Shared Health and across other national partners. A change in probe manufacturer was validated and implemented.

Change in Test Procedure:

- CLL FISH will now be performed using the MetaSystems© CLL FISH probe sets. Please refer to links below for probe set information.

References/Resources:

- XL ATM/TP53 Deletion Probe
<https://metasystems-probes.com/en/probes/xl/d-5046-100-og/>
- XL DLEU/LAMP12/12cen Deletion/Enumeration Probe
<https://metasystems-probes.com/en/probes/xl/d-5055-100-tc/>

Patient Impact:

- CLL testing allows physicians to determine prognostic implications, and target treatments based on test findings.

System Improvements:

- The MetaSystems© CLL probes have greater reliability, which lowers the risk of needing to repeat testing, and allows the laboratory to meet reporting turn-around-times.

More Information:

<https://metasystems-international.com/>

Contact Information:

Dr. Angie Dawson, Cytogeneticist, 204-787-2491, adawson@sharedhealthmb.ca
Dr. Jing Liu, Cytogeneticist, 204-787-2483, jliu@sharedhealthmb.ca